【ChiCTR2000033777】Effects of a live streaming Mindfulness Yoga - Practice Awareness through Cognitive-based Exercise (MY-PACE) Program on balance and gait for People with Parkinson’s Disease: A Randomised Controlled Trial
ChiCTR2000033777
尚未开始
/
/
/
2020-06-12
/
/
Parkinson's disease
Effects of a live streaming Mindfulness Yoga - Practice Awareness through Cognitive-based Exercise (MY-PACE) Program on balance and gait for People with Parkinson’s Disease: A Randomised Controlled Trial
Effects of a live streaming Mindfulness Yoga - Practice Awareness through Cognitive-based Exercise (MY-PACE) Program on balance and gait for People with Parkinson’s Disease: A Randomised Controlled Trial
To examine the comparative effects between Mindfulness Yoga – Practice Awareness through Cognitive-based Exercise (MY-PACE) and usual care service only for Chinese patients with mild-to-moderate PD, on the following physio-psycho-cognitive outcomes: a)functional mobility (primary outcome), b)perceived balance confidence (primary outcome), c)gait, d)PD-related motor symptoms, e)anxiety and depressive symptoms, f)mindfulness, g)cognitive function, and, h)HRQOL.
随机平行对照
其它
Eligible participants will be randomly assigned into one of the following conditions on 1:1 basis using a randomization table produced using computer-assisted random number generator.
Single-blinded
University Fund
/
56
/
2020-06-22
2022-09-30
/
To be eligible for inclusion, individuals must be (1) diagnosed with idiopathic PD (Hoehn and Yahr stage I-III); (2) aged >=18 years; (3) able to walk with or without an assistive device; (4) able to give written consent, and (5) have access to smartphone/ tablet device and Internet connection.；
请登录查看Individuals will be excluded if they: (1) are currently participating in any other behavioural or pharmacological trial; (2) have significant cognitive impairment as indicated by the Hong Kong Montreal Cognitive Assessment 5-min protocol (HK-MoCA), cutoff scores based on the age and education corrected normative data will be used [11] [12], or (3) have serious medical conditions except PD, or other contraindication to mild-to-moderate physical exertion that might limit their full participation (e.g. severe hearing or vision impairment, significant orthopaedic problems, etc.).；
请登录查看香港大學李嘉誠醫學院護理學院
/
香港大學李嘉誠醫學院護理學院的其他临床试验
香港大學李嘉誠醫學院護理學院的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04